Overview
Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain
Status:
Completed
Completed
Trial end date:
2009-09-01
2009-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The primary objective of this study is to assess the efficacy of ataciguat versus placebo in reducing pain intensity in patients with neuropathic pain. The secondary objective is to assess the safety and tolerability of ataciguat versus placebo.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
SanofiTreatments:
5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide
Criteria
Inclusion Criteria:- Patients with chronic neuropathic pain due to diabetic polyneuropathy or a nerve
lesion following surgery. The pain must be present for more than 3 months.
Exclusion Criteria:
- Presence or history of cancer within the past five years
- Patients with a history of HIV infection
- Patients with active hepatitis B or C
- Patients with any pain other than the neuropathic pain of greater or equal severity
- Patients with a diabetes mellitus for less than 6 months
The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.